Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A
Rhea-AI Filing Summary
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Immunome Inc. common stock. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the class, based on 113,250,394 shares outstanding as of May 7, 2026.
The Reporting Persons have shared voting and dispositive power over all 4,832,279 shares and no sole voting or dispositive power. Sirenia is a Delaware limited partnership, and Mr. Silverstein is a U.S. citizen. This amended Schedule 13G reflects ownership of 5% or less of Immunome’s outstanding common stock.
Positive
- None.
Negative
- None.
Key Figures
Shares beneficially owned: 4,832,279 shares
Ownership percentage: 4.3%
Shares outstanding: 113,250,394 shares
+2 more
5 metrics
Shares beneficially owned
4,832,279 shares
Common stock of Immunome Inc. beneficially owned by the Reporting Persons
Ownership percentage
4.3%
Percent of Immunome common stock class held by the Reporting Persons
Shares outstanding
113,250,394 shares
Immunome common shares outstanding as of May 7, 2026
Shared voting power
4,832,279 shares
Shares over which the Reporting Persons share voting power
Shared dispositive power
4,832,279 shares
Shares over which the Reporting Persons share dispositive power
Key Terms
beneficial owner, shared voting power, shared dispositive power, Schedule 13G, +1 more
5 terms
beneficial owner financial
"the beneficial owner of the securities reported herein"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Schedule 13G regulatory
"This amended Schedule 13G reflects ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
percent of class financial
"Percent of class: 4.3%"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
What stake in Immunome Inc. (IMNM) does Sirenia Capital report?
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 4,832,279 shares of Immunome common stock, representing 4.3% of the outstanding class based on 113,250,394 shares outstanding as of May 7, 2026.
Who are the Reporting Persons in this Immunome (IMNM) Schedule 13G/A?
The Reporting Persons are Sirenia Capital Management LP and Alex Silverstein. Sirenia manages investment funds and an account holding Immunome shares, and Mr. Silverstein is the managing member of Sirenia’s general partner. Both disclaim admission of beneficial ownership status.
Does Sirenia Capital own more than 5% of Immunome (IMNM)?
No. The Reporting Persons state beneficial ownership of 4.3% of Immunome’s common stock. The filing notes ownership of 5 percent or less of the class, indicating their stake is below the 5% threshold.
AI-generated analysis. How Rhea-AI works. Not financial advice.